Success Metrics

Clinical Success Rate
100.0%

Based on 15 completed trials

Completion Rate
100%(15/15)
Active Trials
0(0%)
Results Posted
73%(11 trials)

Phase Distribution

Ph phase_1
2
13%
Ph phase_2
5
33%
Ph phase_3
8
53%

Phase Distribution

2

Early Stage

5

Mid Stage

8

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
5(33.3%)
Phase 3Large-scale testing
8(53.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

15 of 15 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(15)

Detailed Status

Completed15

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (13.3%)
Phase 25 (33.3%)
Phase 38 (53.3%)

Trials by Status

completed15100%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT06493604Phase 3

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Completed
NCT04735393Phase 3

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Completed
NCT06424444Phase 3

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Completed
NCT06389214Phase 3

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Completed
NCT03660878Phase 1

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Completed
NCT04674358Phase 2

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Completed
NCT05062330Phase 3

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Completed
NCT05102409Phase 2

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

Completed
NCT04971031Phase 2

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Completed
NCT03709121Phase 1

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Completed
NCT03494504Phase 3

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Completed
NCT03404115Phase 2

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Completed
NCT05424549Phase 2

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Completed
NCT04207736Phase 3

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Completed
NCT05234554Phase 3

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15